Morpholinyl piperidine glycine transporter inhibitors
View Patent ↗The present invention is directed to morpholinyl piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.
1. A compound of the formula I:
wherein:
R 2 is selected from the group consisting of:
(1) phenyl, which is substituted with R 2a , R 2b and R 2c ,
(2) heterocycle, which is substituted with R 2a , R 2b and R 2c ,
(3) C 1-8 alkyl, which is unsubstituted or substituted with 1-6 halogen, hydroxy, —NR 10 R 11 , phenyl or heterocycle, where the phenyl or heterocycle is substituted with R 2a , R 2b and R 2c ,
(4) C 3-6 cycloalkyl, which is unsubstituted or substituted with 1-6 halogen, hydroxy or —NR 10 R 11 ,
wherein R 10 and R 11 are independently selected from:
(a) hydrogen,
(b) —C 1-6 alkyl, which is unsubstituted or substituted with hydroxy, 1-6 fluoro or —NR 12 R 13 , where R 12 and R 13 are independently selected from hydrogen and —C 1-6 alkyl,
(c) —C 3-6 cycloalkyl, which is unsubstituted or substituted with hydroxy, 1-6 fluoro or —NR 12 R 13 ,
(d) benzyl,
(e) phenyl, and
(5) —C 1-6 alkyl-(C 3-6 cycloalkyl), which is unsubstituted or substituted with 1-6 halogen, hydroxy or —NR 10 R 11 ;
R 2a , R 2b and R 2c are independently selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) —C 1-6 alkyl, which is unsubstituted or substituted with:
(a) 1-6 halogen,
(b) phenyl,
(c) C 3-6 cycloalkyl, or
(d) —NR 10 R 11 ,
(4) —O—C 1-6 alkyl, which is unsubstituted or substituted with 1-6 halogen,
(5) hydroxy,
(6) —SCF 3 ,
(7) —SCHF 2 ,
(8) —SCH 3 ,
(9) —CO 2 R 9 ,
wherein R 9 is independently selected from:
(a) hydrogen,
(b) —C 1-6 alkyl, which is unsubstituted or substituted with 1-6 fluoro,
(c) benzyl, and
(d) phenyl,
(10) —CN,
(11) —SO 2 R 9 ,
(12) —SO 2 —NR 10 R 11 ,
(13) —NR 10 R 11 ,
(14) —CONR 10 R 11 , and
(15) —NO 2 ;
R 3 is selected from the group consisting of:
(1) C 1-6 alkyl, which is unsubstituted or substituted with 1-6 halogen, hydroxyl, —NR 10 R 11 , or heterocycle, which is substituted with R 2a , R 2b and R 2c ,
(2) C 3-6 cycloalkyl, which is unsubstituted or substituted with 1-6 halogen, hydroxyl or —NR 10 R 11 ,
(3) —C 1-6 alkyl-(C 3-6 cycloalkyl), which is unsubstituted or substituted with 1-6 halogen, hydroxy or —NR 10 R 11 , and
(4) —NR 10 R 11 , and
(5) heterocycle, which is substituted with R 2a , R 2b and R 2c ;
R 4 and R 5 are independently selected from the group consisting of:
(1) hydrogen, and
(2) C 1-6 alkyl, which is unsubstituted or substituted with halogen or hydroxyl,
or R 4 and R 5 taken together form a C 3-6 cycloalkyl ring;
A is selected from the group consisting of:
(1) —O—, and
(2) —NR 10 —;
m is zero or one, whereby when m is zero R 2 is attached directly to the carbonyl;
and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.
2. The compound of claim 1 of the formula Ia:
or a pharmaceutically acceptable salt thereof or an individual enantiomer or diastereomer thereof.
3. The compound of claim 1 of the formula Ib:
wherein R 4 is C 1-6 alkyl; or a pharmaceutically acceptable salt thereof or an individual enantiomer or diastereomer thereof.
4. The compound of claim 1 wherein R 4 is C 1-3 alkyl and R 5 is hydrogen or C 1-3 alkyl.
5. The compound of claim 4 wherein R 4 is C 1-3 alkyl in the (S) configuration and R 5 is hydrogen.
6. The compound of claim 4 wherein R 4 is methyl and R 5 is hydrogen.
7. The compound of claim 1 wherein R 4 is methyl and R 5 is methyl.
8. The compound of claim 1 wherein R 4 is hydrogen and R 5 is hydrogen.
9. The compound of claim 1 of the formula Ic:
or a pharmaceutically acceptable salt thereof or an individual enantiomer or diastereomer thereof.
10. The compound of claim 1 of the formula Id:
and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.
11. The compound of claim 10 of the formula Id′:
and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.
12. The compound of claim 10 of the formula Id″:
and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.
13. The compound of claim 9 wherein R 2 is selected from the group consisting of:
(1) phenyl, which is substituted with R 2a , R 2b and R 2c ,
(2) thienyl, which is substituted with R 2a , R 2b and R 2c ,
(3) C 1-8 alkyl, which is unsubstituted or substituted with 1-6 halogen, phenyl or —NR 10 R 11 , where the phenyl is substituted with R 2a , R 2b and R 2c ,
(4) C 3-6 cycloalkyl, which is unsubstituted or substituted with 1-6 halogen, hydroxy or —NR 10 R 11 , and
R 2a , R 2b and R 2c are independently selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) —C 1-6 alkyl,
(4) —O—C 1-6 alkyl,
(5) —CF 3 ,
(6) —OCF 3 ,
(7) —OCHF 2 ,
(8) —SCF 3 ,
(9) —SCHF 2 , and
(10) —NH 2 .
14. The compound of claim 13 wherein R 2 is phenyl or thienyl and R 2a , R 2b and R 2c are independently selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) —C 1-6 alkyl,
(4) —O—C 1-6 alkyl,
(5) —CF 3 ,
(6) —OCF 3 ,
(7) —OCHF 2 ,
(8) —SCF 3 ,
(9) —SCHF 2 , and
(10) —NH 2 .
15. The compound of claim 14 wherein R 2 is phenyl and R 2a , R 2b and R 2c are independently selected from the group consisting of:
(1) hydrogen,
(2) fluoro,
(3) chloro,
(4) bromo,
(5) —OCH 3 ,
(6) —CF 3 , and
(7) —NH 2 .
16. The compound of claim 1 wherein R 3 is C 1-6 alkyl or —N(C 1-6 alkyl)(C 1-6 alkyl).
17. The compound of claim 16 wherein R 3 is —CH 2 CH 3 .
18. The compound of claim 16 wherein R 3 is —(CH 2 ) 2 CH 3 .
19. The compound of claim 16 wherein R 3 is cyclopropyl.
20. A compound which is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
21. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a compound of claim 1 or a pharmaceutically acceptable salt thereof.